Literature DB >> 33668302

Emergence of Nosocomial Pneumonia Caused by Colistin-Resistant Escherichia coli in Patients Admitted to Chest Intensive Care Unit.

Mohamed A El-Mokhtar1,2, Enas Daef1, Aliae A R Mohamed Hussein3, Maiada K Hashem3, Hebatallah M Hassan1.   

Abstract

(1) Background: Colistin is a last-resort antibiotic used in treating multidrug-resistant Gram-negative infections. The growing emergence of colistin resistance in Escherichia coli (E. coli) represents a serious health threat, particularly to intensive care unit (ICU) patients. (2)
Methods: In this work, we investigated the emergence of colistin resistance in 140 nosocomial E. coli isolated from patients with pneumonia and admitted to the chest ICU over 36 months. Virulence and resistance-related genes and E. coli pathotypes in colistin-resistant and colistin-sensitive isolates were determined. (3)
Results: Colistin resistance was observed in 21/140 (15%) of the nosocomial E. coli isolates. The MIC50 of the resistant strains was 4 mg/L, while MIC90 was 16 mg/L. Colistin-resistant isolates were also co-resistant to amoxicillin, amoxicillin/clavulanic, aztreonam, ciprofloxacin, and chloramphenicol. The mechanism of colistin resistance was represented by the presence of mcr-1 in all resistant strains. Respectively, 42.9% and 36.1% of colistin-resistant and colistin-sensitive groups were extended-spectrum β-lactamase (ESBL) producers, while 23.8% and 21% were metallo β-lactamase (MBL) producers. blaTEM-type was the most frequently detected ESBL gene, while blaIMP-type was the most common MBL in both groups. Importantly, most resistant strains showed a significantly high prevalence of astA (76.2%), aggR (76.2%), and pic (52.4%) virulence-related genes. Enteroaggregative E. coli (76%) was the most frequently detected genotype among the colistin-resistant strains. (4)
Conclusion: The high colistin resistance rate observed in E. coli strains isolated from patients with nosocomial pneumonia in our university hospital is worrisome. These isolates carry different drug resistance and virulence-related genes. Our results indicate the need for careful monitoring of colistin resistance in our university hospital. Furthermore, infection control policies restricting the unnecessary use of extended-spectrum cephalosporins and carbapenems are necessary.

Entities:  

Keywords:  ESBL; MBL; colistin resistance; enteroaggregative E. coli; mcr-1; multidrug-resistance

Year:  2021        PMID: 33668302     DOI: 10.3390/antibiotics10030226

Source DB:  PubMed          Journal:  Antibiotics (Basel)        ISSN: 2079-6382


  4 in total

1.  Screening of mcr-1 among Gram-Negative Bacteria from Different Clinical Samples from ICU Patients in Alexandria, Egypt: One-Year Study.

Authors:  Amira Elbaradei; Mahrous S Sayedahmed; Gamal El-Sawaf; Sherine M Shawky
Journal:  Pol J Microbiol       Date:  2022-03-30

2.  Molecular Epidemiology of Extensively Drug-Resistant mcr Encoded Colistin-Resistant Bacterial Strains Co-Expressing Multifarious β-Lactamases.

Authors:  Hasan Ejaz; Sonia Younas; Muhammad Usman Qamar; Kashaf Junaid; Abualgasim Elgaili Abdalla; Khalid Omer Abdalla Abosalif; Ayman Ali Mohammed Alameen; Mohammed Yagoub Mohammed Elamir; Naveed Ahmad; Sanaa Samir Mohamed Hamam; Eman Hosney Mohammed Salem; Syed Nasir Abbas Bukhari
Journal:  Antibiotics (Basel)       Date:  2021-04-20

3.  Socioeconomic burden of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa in Korea.

Authors:  Chung-Jong Kim; Kyoung-Ho Song; Jeonghoon Ahn; Hong Bin Kim; Nam-Kyong Choi; Ji Yun Bae; Hee Jung Choi; Younghee Jung; Seung Soon Lee; Ji-Hwan Bang; Eu Suk Kim; Song Mi Moon; Je Eun Song; Yee Gyung Kwak; Shin Hye Chun; Yeon-Sook Kim; Kyung-Hwa Park; Yu Min Kang; Pyoeng Gyun Choe; Shinwon Lee
Journal:  Sci Rep       Date:  2022-08-17       Impact factor: 4.996

4.  Bloodstream infections in adult patients with malignancy, epidemiology, microbiology, and risk factors associated with mortality and multi-drug resistance.

Authors:  Samane Nematolahi; Zahra Shahhosein; Ali Amanati; Sarvin Sajedianfard; Somayeh Khajeh; Shabnam Ghasempour; Salma Mehrangiz
Journal:  BMC Infect Dis       Date:  2021-07-02       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.